Journal
CLINICAL INFECTIOUS DISEASES
Volume 69, Issue -, Pages 544-551Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciz827
Keywords
carbapenem-resistant Acinetobacter; carbapenem-resistant Enterobacteriaceae; carbapenem-resistant Pseudomonas; cefiderocol; Stenotrophomonas maltophilia
Categories
Funding
- Shionogi & Co, Ltd (Osaka, Japan)
Ask authors/readers for more resources
Carbapenem-resistant gram-negative bacteria including Enterobacteriaceae as well as nonfermenters, such as Pseudomonas aeruginosa and Acinetobacter baumannii, have emerged as significant global clinical threats. Although new agents have recently been approved, none are active across the entire range of resistance mechanisms presented by carbapenem-resistant gram-negative bacteria. Cefiderocol, a novel siderophore cephalosporin, has been shown in large surveillance programs and independent in vitro studies to be highly active against all key gram-negative causative pathogens isolated from patients with hospital-acquired or ventilator-associated pneumonia, bloodstream infections, or complicated urinary tract infections. The improved structure, the novel mode of entry into bacteria, and its stability against carbapenemases enables cefiderocol to exhibit high potency against isolates that produce carbapenemases of all classes or are resistant due to porin channel mutations and/or efflux pump overexpression. Resistance to cefiderocol is uncommon and appears to be multifactorial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available